ALK and cancer: reported that PTPN2 loss in CD8+ T cells promoted anti‐tumor immunity.[31] Consistent with these findings, our study has identified PTPN2 as a cancer‐promoting factor, providing a novel therapeutic target for ALK+ ALCL.